Precision Immunotherapy to Improve Sepsis Outcomes
Präzisionsimmuntherapie zur Verbesserung von Sepsis-Outcomes
JAMA · 03.03.2026 · 335 (9) · 775
DOI: 10.1001/jama.2025.24175 ↗Auf einen Blick
Bei 276 Patient:innen mit Sepsis verbesserte eine biomarkerbasierte Präzisionsimmuntherapie die Organfunktion bis Tag 9 häufiger als Placebo. Ein Unterschied in der 28-Tage-Mortalität zeigte sich nicht.
Fragestellung
Verbessert eine nach Makrophagenaktivierungs-ähnlichem Syndrom oder sepsisinduzierter Immunsuppression gesteuerte Präzisionsimmuntherapie die Organfunktion bis Tag 9 bei Sepsis?
Methode
Randomisierte, doppelblinde, doppelt-dummy, placebokontrollierte Studie in 6 Ländern; Behandlung bis zu 15 Tage; Endpunkt: SOFA-Abnahme um mindestens 1,4 Punkte bis Tag 9.
Ergebnisse
Der primäre Endpunkt wurde bei 46/131 (35,1 %) unter Präzisionsimmuntherapie und bei 26/145 (17,9 %) unter Placebo erreicht; Differenz 17,2 % (95 %-KI 6,8 % bis 27,2 %), P = .002. 28-Tage-Mortalität nicht signifikant unterschiedlich.
Schlussfolgerung der Autor:innen
Bei Patient:innen mit Sepsis verbesserte die auf Makrophagenaktivierungs-ähnliches Syndrom und sepsisinduzierte Immunsuppression zielende Präzisionsimmuntherapie die Organfunktion bis Tag 9 im Vergleich zu Placebo.
Kernaussagen
- Primärer Endpunkt häufiger erreicht: 35,1 % vs. 17,9 %
- Differenz 17,2 % (95 %-KI 6,8 % bis 27,2 %)
- 28-Tage-Mortalität nicht signifikant unterschiedlich
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift JAMA, erschienen am 03.03.2026. Verfasst von Evangelos J Giamarellos-Bourboulis und 54 weiteren Autor:innen. Beteiligte Einrichtung: Fourth Department of Internal Medicine, National and Kapodistrian University of Athens, Medical School, Greece. Hauptthemen laut MEDLINE: Immunotherapy, Macrophage Activation Syndrome, Multiple Organ Failure, Precision Medicine. Die Arbeit wurde bisher 133-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Themen: Sepsis
Abstract (Originalsprache)
Importance Sepsis is heterogeneous, and the optimal strategy for tailoring immunotherapy is uncertain.
Objective
To investigate whether precision immunotherapy guided by the presence of macrophage activation–like syndrome or sepsis-induced immunoparalysis improves organ dysfunction by day 9. Design, Setting, and Participants A randomized, double-blind, double-dummy, placebo-controlled clinical trial conducted in 6 countries. Patients with sepsis, defined by Sepsis-3, were included if they had community-acquired or hospital-acquired pneumonia or ventilator-associated pneumonia or bacteremia and sepsis and had displayed either macrophage activation–like syndrome (blood ferritin >4420 ng/mL) or sepsis-induced immunoparalysis (blood ferritin ≤4420 ng/mL and <5000 human leukocyte antigen DR receptors on CD45/CD14 monocytes). The first patient was enrolled August 5, 2021, and the last follow-up, April 29, 2024.
Interventions
Eligible patients were randomized to receive standard care and precision immunotherapy or standard care and placebo. Those in the precision immunotherapy group with macrophage activation–like syndrome received anakinra intravenously (IV) and placebo subcutaneously, and those with sepsis-induced immunoparalysis received subcutaneous recombinant human interferon gamma and IV placebo. Those in the placebo group received both IV and subcutaneous placebo. Treatment was administered for up to 15 days. Main Outcomes and Measures The primary end point was a decrease of at least 1.4 points in the mean Sequential Organ Failure Assessment (SOFA) score from baseline by day 9. The SOFA score evaluates 6 organ systems, ranging from 0, no dysfunction, to 4, failure, and the total score ranges from 0, normal, to 24, most severe form of multiorgan failure. Key secondary outcomes included 28-day mortality.
Results
Of 672 patients assessed for eligibility, 281 were randomized and 276 were included in the primary analysis population (mean [SD] age, 70 [13] years; 93 females [33.7%]; median baseline SOFA score, 9 [IQR, 7-11]). The SOFA decrease end point was attained by 46 of 131 patients (35.1%) in the precision immunotherapy group and by 26 of 145 patients (17.9%) in the placebo group (difference, 17.2% [95% CI, 6.8% to 27.2%]; P = .002). Mortality at 28 days was not statistically significantly different between groups. A total of 1069 serious treatment-emergent adverse events (88.8%) were reported; increased incidence of anemia was noted in the anakinra group; and hemorrhage in the recombinant human interferon gamma group. Conclusions and Relevance Among patients with sepsis, precision immunotherapy targeting macrophage activation–like syndrome and sepsis-induced immunoparalysis improved organ dysfunction by day 9 compared with placebo. Trial Registration ClinicalTrials.gov Identifier: NCT04990232
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Fourth Department of Internal Medicine, National and Kapodistrian University of Athens, Medical School, Greece.
- Hellenic Institute for the Study of Sepsis, Athens, Greece.
- Intensive Care Unit, Ippokrateion General Hospital of Thessaloniki, Thessaloniki, Greece.
- Department of Anesthesiology and Intensive Care, AHEPA Thessaloniki University General Hospital, Thessaloniki, Greece.
- Polyvalent Intensive Care Unit, Sotiria Athens General Hospital of Chest Diseases, Athens, Greece.
- Department of Anesthesiology and Intensive Care, Jena University Hospital, Jena, Germany.
Zitieren
APA
Giamarellos-Bourboulis, E. J., Kotsaki, A., Kotsamidi, I., Efthymiou, A., Koutsoukou, V., Ehler, J., Paridou, A., Frantzeskaki, F., Müller, M. C. A., Pickkers, P., Meylan, S., Nikolopoulos, I., Lupse, M., Gavala, A., Vlachogianni, G., Solomonidi, N., Alevizou, A., Kondili, E., Antoniadou, E., …, & ImmunoSep Study Group (2026). Precision Immunotherapy to Improve Sepsis Outcomes. JAMA, 335(9), 775. https://doi.org/10.1001/jama.2025.24175
Vancouver
Giamarellos-Bourboulis EJ, Kotsaki A, Kotsamidi I, Efthymiou A, Koutsoukou V, Ehler J, et al. Precision Immunotherapy to Improve Sepsis Outcomes. JAMA. 2026;335(9):775. doi:10.1001/jama.2025.24175
BibTeX
@article{GiamarellosBourboulis2026,
author = {Giamarellos-Bourboulis, Evangelos J and Kotsaki, Antigone and Kotsamidi, Ioanna and Efthymiou, Aikaterini and Koutsoukou, Vasiliki and Ehler, Johannes and Paridou, Alexandra and Frantzeskaki, Frantzeska and Müller, Marcella C A and Pickkers, Peter and Meylan, Sylvain and Nikolopoulos, Ioannis and Lupse, Mihaela and Gavala, Alexandra and Vlachogianni, Glykeria and Solomonidi, Nicky and Alevizou, Antonia and Kondili, Eumorfia and Antoniadou, Eleni and Nakou, Maria and Markou, Nikolaos and Hatziagelaki, Erifili and Prekates, Athanassios and Komnos, Apostolos and Bakkerus, Lieke and Slim, Marleen A and Dalekos, George N and Karapanagiotou, Areti and Ktena, Sofia and De Pascale, Gennaro and Koulouras, Vassileios and Psarrakis, Christos and Massa, Eleni and Dakou, Konstantina and Pazvanti, Chrisoula and Ioakeimidou, Aikaterini and Tsangaris, Iraklis and Antonakos, Nikolaos and Vlaar, Alexander P J and Anisoglou, Souzana and Calandra, Thierry and Papaioannou, Vasilios and Myrianthefs, Pavlos and Patrani, Maria and Alamanos, Ioannis and Antonelli, Massimo and van der Meer, Jos W M and van der Poll, Tom and Wiersinga, W Joost and Ntaganou, Maria and Gkeka, Eleni and Bauer, Michael and Mouloudi, Eleni and Netea, Mihai G and ImmunoSep Study Group, ImmunoSep Study Group},
title = {Precision Immunotherapy to Improve Sepsis Outcomes},
journal = {JAMA},
year = {2026},
volume = {335},
number = {9},
pages = {775},
doi = {10.1001/jama.2025.24175}
}
EUVIMED